Acquisition - March 10, 2021
Amgen to acquire Five Prime Therapeutics for USD 1.9 billion
Amgen and Five Prime Therapeutics have announced an agreement under which Amgen will acquire Five Prime Therapeutics for USD 38 per share in cash, representing an equity value of approximately USD 1.9 billion. Five Prime’s lead asset, bemarituzumab, is a Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study […]
Global report - February 25, 2021
Philadelphia – A fertile ground for innovation
Philadelphia has a long legacy of life sciences and success and now, cell and gene therapy is fast becoming a local specialty. Mention Philadelphia, Pennsylvania, in the U.S., and the first thoughts usually go to its role in the nation’s formation and early history: the writing and signing of the Declaration of Independence in 1776 […]
Global report - January 25, 2021
Biogen to develop digital biomarkers of cognitive health
Biogen has announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). The multi-year, observational research study will be launched later in 2021 and will enroll participants including young […]
Global report - November 2, 2020
New England Journal of Medicine condemns Trump’s handling of COVID-19
In an editorial, The New England Journal of Medicine called for replacing “dangerously incompetent” political leadership in the United States. One of the world’s most prestigious medical journals, The New England Journal of Medicine, has never supported or condemned a political candidate before. In an editorial signed by 34 editors, the journal said the Trump […]
Global report - August 19, 2020
Historic partnership aims to tackle antimicrobial resistance
More than 20 biopharmaceutical companies have announced the launch of the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. Through the Fund, pharmaceutical companies will join forces […]
Global report - July 10, 2020
Pfizer starts Phase 3 clinical trials for investigational vaccines
Pfizer has announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines. “The start of four Phase 3 studies across our portfolio of investigational vaccines is a testament to the talented and dedicated colleagues working throughout Pfizer, and the continued commitment to unlock the potential promise and value that […]
